Scarica l'app Stockscreener
58.57
6.30%
3.47
Dopo l'orario di chiusura:
58.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$55.10
Aprire:
$55.395
Volume 24 ore:
3.05M
Relative Volume:
1.33
Capitalizzazione di mercato:
$7.30B
Reddito:
$692.26M
Utile/perdita netta:
$-512.41M
Rapporto P/E:
-13.81
EPS:
-4.24
Flusso di cassa netto:
$-274.36M
1 W Prestazione:
+31.35%
1M Prestazione:
+16.56%
6M Prestazione:
+24.67%
1 anno Prestazione:
+96.94%
Intervallo 1D:
$55.14
$58.62
Intervallo di 1 settimana:
$48.25
$58.62
Portata 52W:
$20.14
$58.62
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Confronta GH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
58.57 | 6.83B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 174.60B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 143.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
664.16 | 52.17B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 32.42B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 30.62B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
The 5 Most Interesting Analyst Questions From Guardant Health’s Q2 Earnings Call - Yahoo Finance
GH Q2 Deep Dive: Strong Volume Growth and Product Expansion Amid Profitability Challenges - ca.finance.yahoo.com
Is Guardant Health Inc. impacted by rising ratesReal Return Trading Plans - newsyoung.net
Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024 - uk.finance.yahoo.com
Exact Sciences Teams Up With Freenome to Take on Guardant Health in Colorectal Cancer Screening - MedCity News
Weekly Market Update: Stocks Rise as Basic Materials and Tech Gain - Morningstar
Guardant Health Surges 7.62% on $250M Volume Despite 396th Market Activity Rank - AInvest
Guardant Health Surges 13% on 197% Volume Spike Ranks 269th in Market Activity - AInvest
Guardant Health stock hits 52-week high at 53.49 USD By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at 53.49 USD - Investing.com
Guardant Health Soars 17.2% on Q2 Earnings Beat - AInvest
Exact Sciences acquires rights to rival Freenome’s blood-based colon cancer test - statnews.com
Multi-Cancer Early Detection Market Set to Revolutionize Cancer Diagnosis by 2034 | Driven by Liquid Biopsy Innovations and AI Integration - PharmiWeb.com
The Oncology Institute, Inc. shares rise 3.94% intraday after American Cancer Society and Guardant Health partnership. - AInvest
American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity - Business Wire
Is It Too Late to Sell Guardant Health Inc.Intraday Trend Analysis for Fast Gains Released - beatles.ru
Why is Guardant Health Inc. stock attracting strong analyst attentionRobust financial gains - Jammu Links News
What drives Guardant Health Inc. stock priceUnlock daily market insights for better trades - Jammu Links News
What is the risk reward ratio of investing in Guardant Health Inc. stockExceptional market positioning - Jammu Links News
Should I hold or sell Guardant Health Inc. stock in 2025Maximize portfolio value with expert tips - Jammu Links News
What catalysts could drive Guardant Health Inc. stock higher in 2025Exceptional trading results - Jammu Links News
How volatile is Guardant Health Inc. stock compared to the marketHarness the power of proven investment plans - Jammu Links News
What institutional investors are buying Guardant Health Inc. stockSignificant capital appreciation - Jammu Links News
Does Guardant Health Inc. stock perform well during market downturnsUnlock powerful portfolio management tools - Jammu Links News
What is Guardant Health Inc. company’s growth strategyMarket-leading growth rates - Jammu Links News
Is Guardant Health Inc. a growth stock or a value stockRapid growth trajectories - Jammu Links News
What are Guardant Health Inc. company’s key revenue driversStrong return on assets - Jammu Links News
Is Guardant Health Inc. stock overvalued or undervaluedAchieve breakthrough performance with smart picks - Jammu Links News
How many analysts rate Guardant Health Inc. as a “Buy”Unlock powerful portfolio management tools - Jammu Links News
Guardant Health, Inc. (NASDAQ:GH) Q2 2025 Earnings Call Transcript - Insider Monkey
Guardant Health Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Guardant Health Reports Strong Q2 2025 Growth - The Globe and Mail
Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference - Yahoo Finance
Guardant Health Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Earnings - Benzinga
Guardant Health's Q2 2025: Unpacking Contradictions in Volume Growth, Medicaid Impact, and Market Strategy - AInvest
Guardant Health’s Strong Performance and Growth Potential Justify Buy Rating Despite V2 Data Delay Concerns - TipRanks
Scotiabank raises Guardant Health stock price target to $60 on strong results - Investing.com Australia
Top Analysts Recommend 3 Strong Buy Stocks: Apellis Pharmaceuticals, Guardant Health, and Silvaco Group - AInvest
Guardant Health Beat Wall Street Expectations And Raised Its Outlook - Finimize
Guardant Health 2025 Q2 Earnings Mixed Results as Net Loss Narrows - AInvest
Guardant Health (GH) Q2 Revenue Up 31% - The Motley Fool
Guardant Health Inc (GH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... - Yahoo Finance
Guardant Health Inc (GH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... By GuruFocus - Investing.com Canada
Guardant Health: Q2 Earnings Snapshot - CTPost
Guardant Health (GH): Navigating Growth, Margins, and Valuation in a Competitive Healthcare Innovation Landscape - AInvest
Earnings call transcript: Guardant Health beats Q2 2025 forecasts, shares rise By Investing.com - Investing.com South Africa
Earnings call transcript: Guardant Health beats Q2 2025 forecasts, shares rise - Investing.com Canada
Guardant Health (GH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Guardant Health (NASDAQ:GH) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales - TradingView
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.96%
1.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):